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An essential component of the neural network regulating ingestive behavior is the brain 5-hydroxytryptamine2C receptor (5-HT2CR),
agonists of which suppress food intake and were recently approved for obesity treatment by the US Food and Drug Administration.
5-HT2CR-regulated appetite is mediated primarily through activation of hypothalamic arcuate nucleus (ARC) pro-opiomelanocortin
(POMC) neurons, which are also disinhibited through a 5-HT1BR-mediated suppression of local inhibitory inputs. Here we investigated
whether 5-HT2CR agonist anorectic potency could be significantly enhanced by coadministration of a 5-HT1BR agonist and whether this
was associated with augmented POMC neuron activation on the population and/or single-cell level. The combined administration of
subanorectic concentrations of 5-HT2CR and 5-HT1BR agonists produced a 45% reduction in food intake and significantly greater in vivo
ARC neuron activation inmice. The chemical phenotype of activated ARC neurons was assessed bymonitoring agonist-induced cellular
activity via calcium imaging in mouse POMC-EGFP brain slices, which revealed that combined agonists activated significantly more
POMC neurons (46%) compared with either drug alone (25% each). Single-cell electrophysiological analysis demonstrated that
5-HT2CR/5-HT1BR agonist coadministration did not significantly potentiate the firing frequency of individual ARC POMC-EGFP cells
comparedwithagonists alone.Thesedata indicate a functional heterogeneityofARCPOMCneuronsby revealingdistinct subpopulations
of POMC cells activated by 5-HT2CRs and disinhibited by 5-HT1BRs. Therefore, coadministration of a 5-HT1BR agonist potentiates the
anorectic efficacy of 5-HT2CR compounds by increasing the number, but not the magnitude, of activated ARC POMC neurons and is of
therapeutic relevance to obesity treatment.
Introduction
Obesity is a primary global health challenge of the 21st century,
with obesity pharmacotherapies representing one of the most
profound unmet clinical needs. The dynamic interplay between
nutritional intake and the biogenic amine 5-hydroxytryptamine
(5-HT), which is derived from the essential dietary amino acid
tryptophan, indicates that 5-HT is inextricably linked to energy
balance (Fernstrom and Wurtman, 1972; Tecott, 2007). Com-
pounds augmenting the bioavailability of 5-HT by blocking its
reuptake and/or stimulating release, such as D-fenfluramine and
sibutramine, have been at the forefront of obesity treatment for
the past 15 years (Lam et al., 2010). However, such compounds
have been withdrawn from clinical use due to off-target effects
(Connolly et al., 1997). Therefore, a greater understanding of the
cellular networks that underlie the effectiveness of these com-
pounds would aid in maximizing their therapeutic potential
and facilitating the generation of more effective 5-HT obesity
therapies.
Past efforts revealed that D-fenfluramine requires func-
tional Gq-coupled 5-HT2C receptors (5-HT2CRs) and Gi-
coupled 5-HT1B receptors (5-HT1BRs) to suppress appetite
(Tecott et al., 1995; Lucas et al., 1998). Through these receptors,
D-fenfluramine modulates the melanocortin system of the arcu-
ate nucleus of the hypothalamus (ARC), a key energy balance
network (Heisler et al., 2002, 2006; Sohn et al., 2011). 5-HT-
mediated appetite through the engagement of the ARC mela-
nocortin system occurs via a three-pronged mechanism: (1)
direct activation of anorectic pro-opiomelanocortin (POMC)
neurons (the endogenous melanocortin receptor agonist) via
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5-HT2CRs, (2) indirect 5-HT1BR-mediated disinhibition of anorectic
POMC neurons via suppression of local inhibitory inputs, and
(3) direct inhibition of orexigenic agouti-related protein (AgRP)
neurons (the endogenous melanocortin receptor antagonist/in-
verse agonist; Heisler et al., 2002, 2006; Sohn et al., 2011). Fur-
thermore, 5-HT2CR action exclusively on POMC neurons is
required for D-fenfluramine to exert its anorectic effect (Xu et al., 2008,
2010), demonstrating the therapeutic relevance of the 5-HT-
melanocortin axis. Indeed, the significance of this system in en-
ergy balance regulation was realized in the summer of 2012 when
the US Food and Drug Administration approved a 5-HT2CR ag-
onist (Lorcaserin; Arena Pharmaceuticals) for obesity treatment.
Here we investigated means with which to improve the ano-
rectic therapeutic profile of this new class of obesity pharmaco-
therapy. In light of 5-HT’s bimodal activation of ARC POMC
neurons via its concerted action at 5-HT2CRs and 5-HT1BRs, we
examined whether a net gain in 5-HT2CR agonist anorectic effect
could be obtained by coadministration with a 5-HT1BR agonist
and, if so, whether this was associated with increased efficacy of
POMC neuron activation on either the population or single-cell
level.
Materials andMethods
Animals. Transgenic mice on a C57BL/6 background expressing en-
hanced green fluorescent protein (EGFP) under the control of POMC
regulatory elements (POMC-EGFPmice; generous gift fromProfs. Rich-
ard Simerly and Malcolm Low; Heisler et al., 2002) and wild-type
C57BL/6 mice were group housed and maintained on a 12:12 light-dark
cycle (lights on at 0700) with ad libitum access to chow diet and water
unless otherwise stated. All experiments were in accordance with the UK
Animals (Scientific Procedures) Act 1986.
Drugs. (4aR)-8,9-Dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]qui-
noxalin-5(6H)-one (WAY-161503; Tocris Bioscience) and 5-propoxy-3-
(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[3,2-b]pyridine hydrochloride
(CP-94253;TocrisBioscience)wereusedas selective 5-HT2CRand5-HT1BR
agonists, respectively. Drugs were dissolved in distilled water and adminis-
tered in a volume of 10ml/kg of body weight.
Effect of 5-HT2CR and 5-HT1BR agonists on acute food intake. Single
housed C57BL/6 mice (n  30) received a habituation intraperitoneal
injection of vehicle before a 24 h fast from 0900 h (lights on 0700/off
1900). Mice were then treated intraperitoneally with vehicle, WAY-
161503 (5, 10, 20 mg/kg), CP-94253 (5, 10, 20 mg/kg), or a combined
dose ofWAY-161503 (10mg/kg) andCP-94253 (0, 5, 10, 20mg/kg). One
hour postinjection, chow pellets were replaced and the 4 h food intake
was measured. These studies were performed using a within-subject ex-
perimental design with a minimum 3 d treatment-free period.
Immunohistochemistry. To assess in vivo ARC neuronal activity, ad
libitum fed or 24 h fasted C57BL/6 mice were treated intraperitoneally
with saline, 10 mg/kg WAY-161503, 20 mg/kg CP-94253, or combined
10mg/kgWAY-161503 20mg/kgCP-94253 (n 10 per treatment) for
2 h following the onset of the light cycle (0900
h). Two hours later,micewere terminally anes-
thetized, transcardially perfused with 0.9% sa-
line and then 10% neutral buffered formalin
(Sigma), and brains were extracted, prepared,
coronally sectioned (25m), andprocessed for
cFOS immunoreactivity (FOS-IR) as described
previously (Alon et al., 2009; Lam et al., 2009;
Marston et al., 2011) using an anti-cFOS rabbit
primary antibody (1:8000, catalog #PC38; Cal-
biochem) and a biotinylated donkey anti-
rabbit secondary antibody (1:1000, catalog
#711-065-152, Stratech). Images of FOS-IR
were generated and analyzed using an Axios-
kop IImicroscope (Carl Zeiss) andAdobePho-
toshop CS5 software. Quantitative analysis of
manually counted FOS-IR cells was conducted
at the rostral ARC (1.58 to 1.94 mm from
bregma) and the caudal ARC (2.18 to2.46 mm from bregma; Paxi-
nos and Franklin, 2001).
Tissue preparation for calcium imaging and electrophysiology. Coronal
brain slices (180 m thick) containing the ARC (1.58 to 1.94 mm
bregma) were taken from ad libitum fed POMC-EGFPmice 2 h after the
onset of the light cycle. Slices were prepared as described previously
(Heisler et al., 2002, 2006; Blot et al., 2009) andmaintained in an artificial
cerebrospinal fluid solution containing the following (inmM): 126 NaCl,
2.5 KCl, 21.4 NaHCO3, 1.2 NaH2PO4, 10 glucose, 2 Na pyruvate, 1.2
MgCl2, and 2.4 CaCl2, pH 7.3, gassed with 95% O2 and 5% CO2.
Calcium imaging. Brain slices from male and female POMC-EGFP
(28  1 d, n  9) mice were loaded with fura-2 AM (9.6 M, 0.04%
pluronic acid, 34–36°C for 20 min, followed by a 20 min washout).
Imaging was performed at 34–36°C with an Olympus FluoView
1000MPE two-photon laser-scanning microscope, equipped with a
MaiTai DeepSee laser (Spectra-Physics) tuned to 790 nm, and via an
LUMPlanFI/IR 40 (numerical aperture 0.8) objective. Images were
acquired at a frame rate of 5.4 s and spatial averages of somatic fluores-
cence were monitored as agonists were applied to the bath perfusion.
Fluorescence values (F) were corrected for linear bleaching, background
subtracted, and expressed as the percentage F/F baseline.
Electrophysiology. Cell-attached current-clamp recordings were
performed on brain slices from male and female (7:14) POMC-EGFP
(38  3 d, n  21) mice, at 32–34°C using an EPC-10 amplifier and
Patchmaster software (HEKA Elektronik). Action potentials were de-
tected using MiniAnalysis software (Synaptosoft), and interspike inter-
vals assessed before and after bath application of agonists and expressed
as percentage change from baseline.
Data analysis. Data were analyzed with Student’s t tests, one-way
ANOVA, repeated-measures ANOVA, or  2 followed by Tukey’s or  2
post hoc tests where appropriate. For all analyses, significance was as-
signed at p 0.05. Data are presented as mean SEM.
Results
Identification of subanorectic concentrations of 5-HT2CR and
5-HT1BR agonists
5-HT2CR agonist WAY-161503 and 5-HT1BR agonist CP-94253
suppress appetite (Lee et al., 2002; Heisler et al., 2006;
Rosenzweig-Lipson et al., 2006). We first performed a dose–re-
sponse analysis for 5-HT2CR agonist WAY-161503 (5, 10, and 20
mg/kg, i.p.) and 5-HT1BR agonist CP-94253 (5, 10 and 20mg/kg,
i.p.) to identify subanorectic concentrations in 24 h fasted mice
(n  10 per treatment). The highest dose of WAY-161503 (20
mg/kg, i.p.) suppressed feeding (Fig. 1A, F(3,49)  4.247, p 
0.010) and none of the concentrations of CP-94253 used sig-
nificantly influenced 4 h food intake (Fig. 1B, F(3,50)  1.998,
p  0.127). Nonanorectic concentrations of 10 mg/kg WAY-
161503 and 5, 10, and 20 mg/kg CP-94253 were selected for
future analyses.
Figure 1. CombinedWAY-161503 and CP-94253 significantly reduce feeding at concentrations that alone are not anorectic.A,
The 5-HT2CR agonist WAY-161503 (20 mg/kg, i.p.) significantly suppresses 4 h feeding compared with vehicle (**p 0.010). B,
The 5-HT1BR agonist CP-94253 does not significantly influence 4 h feeding. C, Combined subanorectic concentrations of WAY-
161503 (10 mg/kg) and CP-94253 (20 mg/kg) significantly suppress 4 h food intake compared with saline and individually
administrateddrugs (***p0.001, salineCP-94253at 0, 5, 10, 20mg/kg comparedwith10mg/kgWAY-161503CP-94253
at 0, 5, 10, 20mg/kg; ##p 0.008, 10mg/kgWAY-161503 10mg/kg CP-94253; and ###p 0.001, 10mg/kgWAY-161503
20 mg/kg CP-94253 compared with saline; n 10 per treatment).
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Combined nonanorectic concentrations
of 5-HT2CR and 5-HT1BR agonists
significantly suppress food intake
To investigate the effect of a combined
nonanorectic dose of a 5-HT2CR agonist
with increasing nonanorectic concentra-
tions of 5-HT1BR agonists on acute feed-
ing behavior, 24 h fasted C57BL/6 mice
were treated with either saline  CP-
94253 (0, 5, 10, or 20 mg/kg) or 10 mg/kg
WAY-161503 CP-94253 (0, 5, 10, or 20
mg/kg) and 4 h food intake measured
(n  10 per treatment). Again, saline, 10
mg/kg WAY-161503, and 5, 10, and 20
mg/kg CP-94253 had no significant effect
on feeding behavior alone (Fig. 1C). In
contrast, combining CP-94253 (5, 10, and
20 mg/kg) with 10 mg/kg WAY-161503
dose-dependently enhanced 5-HT2CR
agonist anorectic potency (Fig. 1C, main
effect of treatment, F(1,89)  14.686, p 
0.001;main effect ofCP-94253 concentra-
tions, F(3,89)  7.381, p  0.001; interac-
tion between treatment and CP-94253 concentration, F(3,89) 
1.382, p  0.254). Indeed, 10 mg/kg WAY-161503 combined
with CP-94253 suppressed 4 h feeding by 26% at 10 mg/kg
(Tukey’s post hoc, p 0.008) and suppressed feeding by 45%at 20
mg/kg (Tukey’s post hoc, p 0.001), despite these concentrations
of CP-94253 having no significant effect on feeding when com-
bined with saline. These data indicate that the efficiency of a
5-HT2CR agonist in inducing anorexia is significantly increased
in conjunction with a 5-HT1BR agonist.
Combined nonanorectic concentrations of 5-HT2CR and
5-HT1BR agonists significantly increase ARC FOS-IR
We next sought to investigate the neural mechanism underlying
the observed potentiation of anorexia by combining a 5-HT2CR
agonist with a 5-HT1BR agonist. Based on previous reports indi-
cating that both 5-HT2CR and 5-HT1BR agonists influence the
activity of ARCmelanocortin neurons (Heisler et al., 2002, 2006;
Lam et al., 2008; Sohn et al., 2011), we first examined in vivoARC
neuronal activation using FOS-IR. We observed that concentra-
tions of the 5-HT2CR (10 mg/kg) and 5-HT1BR (20 mg/kg) ago-
nists that did not influence feeding when administered alone also
did not alter ARC neuronal activity (Fig. 2). In contrast, com-
bined 5-HT2CR agonist (10 mg/kg) with a 5-HT1BR agonist (20
mg/kg) substantially increased rostral (1.58 to1.82mm from
bregma) ARC FOS-IR compared with saline in both ad libitum
fed (Fig. 2A–E, F(3,22) 5.944, p 0.0049) and 24 h fasted mice
(Fig. 2F–J, F(3,23)  3.774, p  0.027, n  6–7 per treatment).
Neither individual nor combined drug treatment significantly
influenced the activity of caudal (2.18 to2.46mmfrombregma)
ARC neurons in either ad libitum fed (saline, 118.4 16.3; WAY-
161503, 133.5 13.0; CP-94253, 121.3 25.5; WAY-161503
CP-94253, 155.0  22.2 FOS-IR neurons, F(3,23)  0.808, p 
0.504) or 24 h fasted mice (saline, 84.2  11.1; WAY-161503,
92.3  8.7; CP-94253, 63.0  9.5; WAY-161503  CP-94253,
91.3  8.4 FOS-IR neurons, F(3,24)  2.134, p  0.126). These
data suggest that the population of ARC neurons activated by
5-HT2CR and 5-HT1BR agonists lie in a particular subregion of the
ARC, the rostral portion.
Combined 5-HT2CR and 5-HT1BR agonists significantly
increase the number of responsive ARC POMC neurons
To clarify the chemical phenotype of rostral ARC neurons acti-
vated by combined 5-HT2CRs and 5-HT1BRs agonists, we exam-
ined changes in intracellular calcium concentrations in acute
brain slices from POMC-EGFP mice loaded with fura-2 AM us-
ing multiphoton fluorescence imaging (Fig. 3A). Approximately
25% of POMC neurons responded to 20MWAY-161503 (12 of
45) and 200 nM CP-94253 (19 of 66) alone. In contrast, by com-
bining 20 M WAY-161503 with 200 nM CP-94253, 46% of
ARC POMC neurons (34 of 74) were responsive, significantly
more than individual agonists alone (Fig. 3B,C, 2 (2)  6.38,
p  0.041, n  185). Illustrating that CP-94253’s effects on
POMC activity are mediated via presynaptic action at 5-HT1BRs,
both the synaptic blocker tetrodotoxin (1 M) and the GABAA
receptor antagonist gabazine (3 M) prevented CP-94253’s ef-
fects on POMCactivity (0 of 27 and 3 of 42, respectively, 2 (2)
15.4, p  0.001, compared with CP-94253 alone, n  135),
whereas gabazine (3 M) did not influence WAY-161503’s effect
(2 (1)  0.971E-02, p  0.922, compared with WAY-161503
alone, n 53; Fig. 3B). These findings are consistent with previ-
ous reports indicating that a 5-HT2CR agonist activates25% of
POMCneurons (Sohn et al., 2011) and reveal for the first time the
proportion of POMC neurons activated by a 5-HT1BR agonist.
The finding that the 5-HT2CR agonist and 5-HT1BR agonist acti-
vated a similar percentage of POMC neurons illustrates the im-
portance of modulating GABAergic tone on POMC activity in
5-HT’s appetitive effects. When combined, the 5-HT2CR and
5-HT1BR agonists significantly increased the number of ARC
POMC neurons activated on a population level.
POMCARC neurons increase firing rate in response to
individual and combined 5-HT2CR and 5-HT1BR agonists
To explore the nature of ARC POMC neuronal activation in re-
sponse to WAY-161503 and CP-94253 on a single-cell level,
we used cell-attached electrophysiological recording to assess
changes in firing frequency in acute brain slices isolated from
POMC-EGFP mice. Recordings were made from ventromedial
ARC POMC neurons 1.58 to 1.94 mm from bregma where
the preponderance of 5-HT responding POMC neurons localize
(Sohn et al., 2011). Changes in firing frequency weremeasured as
Figure 2. Combined WAY-161503 and CP-94253 significantly increase ARC FOS-IR compared with agonists administrated
individually. A, F, Quantitative analysis of FOS-IR neurons in rostral ARC (bregma levels from1.58 mm to1.94 mm); combi-
nationof 10mg/kgWAY-161503and20mg/kgCP-94253 increases rostral ARCFOS-IR inad libitum fed (A) and24h fastedmice (F )
(*p 0.027, **p 0.0049 compared with saline; n 6–7 per treatment). B–E and G–J, Representative images of rostral ARC
FOS-IR (1.58mm to1.94mm from bregma) in ad libitum fed (B–E) and 24 h fasted (G–J ) mice treated with saline (B,G), 10
mg/kgWAY-161503 (C,H ), 20 mg/kg CP-94253 (D,I ), or 10 mg/kgWAY-161503 20mg/kg CP-94253 (E,J ). 3V indicates third
ventricle; ME, median eminence. Scale bar, 50m (B–E, G–J ).
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a percentage change of an interspike interval from baseline (Fig.
4A–C). ARC POMC neurons treated with 20 M WAY-161503
and 200 nM CP-94253 administered individually and in combi-
nation showed a substantially higher increase in firing frequency
(12.8  6.5%, 25.1  13.2%, and 37.7  9.7%, respectively,
n  19) and did not have a significantly different effect on the
degree of POMC neuron activation (Fig. 4D, one-way ANOVA,
F(2,18) 1.311, p 0.297, n 6–7 per treatment).Thesedata reveal
that whereas combining 5-HT2CRs and 5-HT1BRs agonists recruits a
greater number of ARC POMC neurons, on a single-cell level, com-
binedagonist administration fails topotentiate the actionof eitherdrug
alone.
Discussion
Lorcaserin, a 5-HT2CR agonist soon to reach the clinical setting
(Smith et al., 2010), was the first new approved obesity treatment
by the FDA in 13 years. Here we investigated means with which
to improve the anorectic therapeutic profile of 5-HT2CR ago-
nists. Utilizing concentrations of com-
pounds that did not influence feeding,
we observed that when combining a
5-HT2CR agonist with a 5-HT1BR agonist,
a significant suppression of food intake
was obtained. Illustrating a mechanism
underlying this effect, we report that
5-HT2CR and 5-HT1BR agonist coapplica-
tion produced a significant increase in the
activity of the key appetitive regulator
POMC in the ARC on the population
level, but not the single-cell level.
POMC is a component of the melano-
cortin system and acts as a principal gate-
way through which multiple metabolic
cues signal (Broberger, 2005; Zhou et al.,
2005; Lam et al., 2010; Pandit et al., 2011).
Indeed, both the critical appetitive neu-
rotransmitter 5-HT and the adipocyte-
derived hormone leptin reciprocally
regulate the activity of POMC and AgRP neurons by directly
activating POMC neurons, inhibiting GABAergic inputs onto
POMC neurons, and directly inhibiting AgRP neurons (Cowley
et al., 2001; Heisler et al., 2002, 2006; Zhou et al., 2005). The
important role of GABA in the mediation of POMC tone in the
regulation of energy balance has been revealed in a recent study
demonstrating that a primary effect of leptin on appetite and
bodyweight ismediated directly throughmodulation of GABAe-
rgic neurotransmission (Vong et al., 2011). We reported previ-
ously that half the concentration of the 5-HT1BR agonist CP-
94253 was sufficient to reduce inhibitory postsynaptic currents
onto POMC neurons compared with the concentration required
to directly inhibit the activity of AgRP neurons (Heisler et al.,
2006). This is consistent with the localization of 5-HT1BRs, which
are primarily heteroreceptors influencing the release of other
neurotransmitters such as GABA (Stanford and Lacey, 1996).
The in vivo feeding data together with the calcium imaging and
electrophysiological data presented here indicate that the ef-
fect of 5-HT1BR agonists on appetite is associated with an
increase in ARC POMC neuron disinhibition via a suppres-
sion of local GABAergic inputs, and that this is as important as
direct stimulation of POMC neurons via 5-HT2CRs in medi-
ating 5-HT-induced anorexia.
The identification of functional heterogeneity in ARC
POMC neurons was recently revealed in a study showing that
POMC neurons responsive to leptin were distinct from those
responsive to a 5-HT2CR agonist (Sohn et al., 2011). The data
presented here further unravel the functional response of
POMC neurons to 5-HT2CR and 5-HT1BR agonists and sug-
gest an additional level of dissociation. Specifically, within the
rostral ARC, individual 5-HT2CR and 5-HT1BR agonists alone
activate 25% of POMC neurons each and, when combined,
activate 46% of POMC neurons. Data obtained on a single-
cell level reveal that 5-HT2CR and 5-HT1BR coadministration
is not more effective at activating POMC neurons than indi-
vidual agonists: they all stimulate POMC neurons to a similar
extent. Together, the data indicate that a primary effect of
agonists is achieved via activation of distinct subpopulations
of POMC neurons, those expressing 5-HT2CRs (Fig. 4Ei) and
those receiving inhibitory inputs expressing 5-HT1BRs (Fig.
4Eii), agonists that when combined thereby significantly in-
crease the proportion of POMC neurons activated. These data
provide an additional functional dissociation of ARC POMC
Figure 3. Combined WAY-161503 and CP-94253 increases ARC POMC intracellular calcium concentrations compared with
individual agonists.A, Coronal ARCPOMC-EGFPbrain slice illustratingEGFPneurons (green) loadedwith fura-2 (red), dual-labeling
(yellow, white arrowheads). 3V indicates third ventricle. Scale bar, 50m. B, Combination of 20M WAY-161503 and 200 nM
CP-94253 increases intracellular calcium concentrations in ARC POMC-EGFP neurons compared with individual treatments (*p
041, n 185 cells). 1 M tetrodotoxin (TTX) and 3 M gabazine block the effect of 200 nM CP-94253 on POMC-EGFP activity
(***p0.001,n135 cells),whereas 3Mgabazinehas no effect on20MWAY-161503onPOMC-EGFP cells ( p0.922,n
53 cells). C, Representative trace of POMC-EGFP neuron increasing intracellular calcium concentrations shown by reduced fluores-
cence ( F) expressed asF/F to the combined dose of 20M WAY-161503 and 200 nM CP-94253.
Figure 4. WAY-161503 and CP-94253 increase the firing rate of ARC POMC neurons. A,
Representative diagram of POMC-EGFP neuron interspike interval (ISI) in response to
coapplication of 20 M WAY-161503 and 200 nM CP-94253 recorded in a cell-attached
electrophysiological configuration (white arrow, baseline trace expanded in B and black
arrow, treatment trace expanded in C). D, Application of 20 M WAY-161503, 200 nM
CP-94253, and 20 M WAY-161503  200 nM CP-94253 achieve a similar degree of
reduction in the ISI of ARC POMC-EGFP neurons (n 6 –7 per treatment). E, Proposed
model of the mechanism through which 5-HT2CR and 5-HT1BR agonists increase ARC POMC
neuron activity. Ei, POMC neurons are directly activated by WAY-161503 via Gq-coupled
5-HT2CRs expressed on POMC neurons. Eii, POMC neurons are disinhibited/indirectly acti-
vated by CP-94253 via Gi-coupled 5-HT1BR-expressing GABAergic projections onto POMC.
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neurons within the rostral ARC and further clarify the heter-
ogeneity of this important population of cells influencing en-
ergy balance.
In summary, we report a significant reduction in food in-
take by combining a 5-HT2CR agonist with a 5-HT1BR agonist
at concentrations that alone do not influence feeding—a com-
bination of agonists that significantly increased POMC neu-
ron activity on a population level. The data obtained therefore
provide an effective means of stimulating a greater proportion
of these critical appetitive cells, highlight the heterogeneity
of ARC POMC neurons, and illustrate the importance of
GABAergic modulation of POMC neurons in 5-HT-induced
anorexia. These data reveal a powerful means with which it is
possible to augment the anorectic potency of a new class of
obesity pharmacotherapy, 5-HT2CR agonists.
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